NCT07223411 2025-11-26Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic MelanomaUniversity of PittsburghRecruiting20 enrolled
NCT07091695 2025-11-12Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+IpilimumabBristol-Myers SquibbCompleted100 enrolled